Page 2

1

2


IN THE CLAIMS:

Please amend claim 38 to read as follows. All claims pending, including those unchanged by the present amendment, are reproduced below for the convenience of the Examiner.


- 1. (Original) A method for delivery of a compound to the surface of, into or across a biological barrier, the method comprising contacting the barrier with a composition comprising the compound and a delivery-enhancing transporter,

 wherein the delivery-enhancing transporter comprises sufficient guanidino or amidino moieties to increase delivery of the compound into or across the barrier compared to delivery of the compound in the absence of the delivery-enhancing transporter.
- 1 2. (Original) The method of claim 1, wherein the delivery-enhancing 2 transporter comprises a peptide backbone.
 - 3. (Original) The method of claim 1, wherein the delivery-enhancing transporter comprises a non-peptide backbone.
- 1 **4.** (Original) The method of claim 1, wherein the delivery-enhancing 2 transporter comprises from 6 to 50 guanidino or amidino moieties.
- 5. (Original) The method of claim 4, wherein the delivery-enhancing transporter comprises from 7 to 15 guanidino moieties.
- 6. (Original) The method of claim 1, wherein the delivery-enhancing transporter comprises at least 6 contiguous subunits which each include a guanidino or amidino moiety.

Page 3



Page 4



Page 5

1 (Original) The method of claim 21, wherein the composition is 2 administered by a transdermal patch. 1 (Original) The method of claim 1, wherein the compound is a therapeutic 2 agent for a condition selected from the group consisting of Crohn's disease, ulcerative colitis, 3 gastrointestinal ulcers, peptic ulcer disease, and abnormal proliferative diseases. 1 27. (Original) The method of claim 26, wherein the compound is a therapeutic 2 for ulcers and is selected from the group consisting of an H₂ histamine inhibitor, an inhibitor of 3 the proton-potassium ATPase, and an antibiotic directed at *Helicobacter pylori*. 1 28. (Original) The method of claim 1, wherein the compound is a therapeutic 2 agent for treating a bronchial condition selected from the group consisting of cystic fibrosis, 3 asthma, allergic rhinitis, and chronic obstructive pulmonary disease. 1 (Original) The method of claim 1, wherein the therapeutic agent is an 29. 2 antiinflammatory agent selected from the group consisting of a corticosteroid, cromolyn, and 3 nedocromil. (Original) The method of claim 1, wherein the compound is a therapeutic 1 2 agent for treating ischemia, Parkinson's disease, schizophrenia, cancer, acquired immune 3 deficiency syndrome (AIDS), infections of the central nervous system, epilepsy, multiple 4 sclerosis, neurodegenerative disease, trauma, depression, Alzheimer's disease, migraine, pain, 5 and a seizure disorder. 1 (Original) The method of claim 1, wherein the compound is selected from 2 the group consisting of cyclosporin, insulin, a vasopressin, a leucine enkephalin, calcitonin, 5-3 fluorouracil, a salicylamide, a β-lactone, an ampicillin, a penicillin, a cephalosporin, a β-

Page 6

1

2

3

4

1

2

lactamase inhibitor, a quinolone, a tetracycline, a macrolide, a gentamicin, acyclovir, ganciclovir,
 a trifluoropyridine, and pentamidine.

l	32. (Original) A composition comprising:
2	an effective amount of a biologically active agent;
3	a delivery-enhancing transporter having sufficient guanidino or amidino moieties to
4	increase delivery of the biologically active agent across a biological barrier
5	compared to the delivery of the biologically active agent in the absence of the
5	transporter; and
7	a pharmaceutically acceptable carrier.

- 33. (Original) The composition of claim 32, wherein the biologically active agent is selected from the group consisting of antiviral agents, antibacterial agents, antifungal agents, antiproliferative agents, immunosuppressive agents, vitamins, analgesic agents and hormones.
- 34. (Original) The composition of claim 33, wherein the biologically active agent is an antiviral agent selected from the group consisting of acyclovir, famciclovir, ganciclovir, foscarnet, idoxuridine, sorivudine, trifluridine, valacyclovir, cidofovir, didanosine, stavudine, zalcitabine, zidovudine, ribavirin and rimantatine.
- 35. (Original) The composition of claim 32, wherein the biologically active agent is an antibacterial agent selected from the group consisting of nafcillin, oxacillin, penicillin, amoxacillin, ampicillin, cefotaxime, ceftriaxone, rifampin, minocycline, ciprofloxacin, norfloxacin, erythromycin and vancomycin.
 - 36. (Original) The composition of claim 32, wherein the biologically active agent is an antifungal agent selected from the group consisting of amphotericin, itraconazole,

Page 7

- 3 ketoconazole, miconazole, nystatin, clotrimazole, fluconazole, ciclopirox, econazole, naftifine,
- 4 terbinafine and griseofulvin.
- 1 37. (Original) The composition of claim 32, wherein the biologically active
- 2 agent is an antineoplastic agent selected from the group consisting of pentostatin, 6-
- 3 mercaptopurine, 6-thioguanine, methotrexate, bleomycins, etoposide, teniposide, dactinomycin,
- 4 daunorubicin, doxorubicin, mitoxantrone, hydroxyurea, 5-fluorouracil, cytarabine, fludarabine,
- 5 mitomycin, cisplatin, procarbazine, dacarbazine, paclitaxel, colchicine, and the vinca alkaloids.
- 1 38. (Currently amended) The composition of claim 32, wherein the biologically
- 2 active agent is an immunosuppressive agent selected from the group consisting of methotrexate,
- 3 azathioprine, fluorouracil, hydroxyurea, 6-thioguanine, chclophosphamide, mechloroethamine
- 4 hydrochloride, carmustine, cyclosporine, taxol or a phosphate-cleavable taxol conjugate,
- 5 tacrolimus, vinblastine, dapsone and sulfasalazine.
- 1 39. (Original) The composition of claim 32, wherein the biologically active
- 2 agent is an analysesic agent selected from the group consisting of lidocaine, bupivacaine,
- 3 novocaine, procaine, tetracaine, benzocaine, cocaine, mepivacaine, etidocaine, proparacaine
- 4 ropivacaine and prilocaine.
- 1 40. (Original) The composition of claim 33, wherein the delivery enhancing
- 2 transporter is a peptide having from about 6 to about 15 amino acids residues wherein from 6 to
- 3 about 12 residues are selected from the group consisting of L-arginine, D-arginine, L-
- 4 homoarginine and D-homoarginine.